Design and preclinical profile of CH5183284/Debio 1347, a novel orally available and selective FGFR inhibitor acting on a gatekeeper mutant of FGFR2

Poster available upon request, please contact our Communication Coordinator

H. Ebiike (1), N. Taka (1), Y. Nakanishi (1), N. Akiyama (1), F. Sawamura (2), K. Morikami (1), M. Matsushita (1), M. Ohmori (1), K. Takami (1), I. Hyohdoh (1), M. Kohchi (1), T. Hayase (1), H. Nishii (1), N. Ishii (1), H. Matsuoka (1)

Abstract – Presented at AACR 2014, San Diego, CA, USA

(1) Pharmaceutical Co., Ltd., Japan

(2) Chugai Research Institute for Medical Science, Inc., Japan